<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02140515</url>
  </required_header>
  <id_info>
    <org_study_id>royan-Emb-018</org_study_id>
    <nct_id>NCT02140515</nct_id>
  </id_info>
  <brief_title>Comparison of Assisted Reproductive Technology (ART) Outcomes Between Two Protocols of Induction of Ovulation in Patients With Hypogonadotropic Hypogonadism</brief_title>
  <official_title>Comparison of Assisted Reproductive Technology (ART) Outcomes Between Two Protocols of Induction of Ovulation by Using Recombinant Luteinizing Hormone (rLH) and Recombinant Follicle Stimulating Hormone (rFSH) in Patients With Hypogonadotropic Hypogonadism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royan Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royan Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We wanted to compare the Assisted Reproductive Technology (ART) outcomes between two&#xD;
      protocols of induction of ovulation in patients with Hypogonadotropic Hypogonadism. In the&#xD;
      beginning, all patients receive Recombinant Follicle Stimulating Hormone (Gonal-F) and&#xD;
      Recombinant Luteinizing Hormone (Luveris). When at least one follicle reaches 14 mm in&#xD;
      diameter, Luveris alone is administered for group A and both drugs Gonal-F and Luveris for&#xD;
      group B. Finally Assisted Reproductive Technology (ART) results are compared between the two&#xD;
      groups.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this single blind randomized clinical trial, 90 women with a clinical history of&#xD;
      hypogonadotrophic hypogonadism who stopped any treatment with gonadotrophins &gt;1 month before&#xD;
      study, with a negative progesterone challenge test, low serum gonadotrophins (Luteinizing&#xD;
      Hormone (LH) and Follicle Stimulating Hormone (FSH) less than 5.0 IU/l) and oestradiol (less&#xD;
      than 100 pg/ml) and normal serum concentrations of thyroid stimulating hormone (TSH),&#xD;
      testosterone and prolactin within 6 months before the start of treatment are studied in the&#xD;
      Royan Institute. Other causes of infertility are excluded from the study. All patients&#xD;
      receive treatment with recombinant follicle stimulating hormone (Gonal-F) and recombinant&#xD;
      luteinizing hormone (Luveris). When at least one follicle reaches 14 mm in diameter, 4mg/day&#xD;
      oestradiol is administered and patients are randomly divided into two groups: Luveris alone&#xD;
      (intervention group) and continued treatment with both drugs Gonal-F and Luveris (control&#xD;
      group). When at least one follicle detects a mean diameter of â‰¥18 mm and serum estradiol&#xD;
      level reaches 500-2000 pg/ml, ovarian stimulation is stopped and injection of 10000 IU Human&#xD;
      Chorionic Gonadotrophin (hCG) is administrated.&#xD;
&#xD;
      At the end, the number and size of ovarian follicles, endometrial thickness on the day of&#xD;
      injection of Human Chorionic Gonadotrophin (hCG), the number of oocytes retrieved, the number&#xD;
      of good quality embryos, chemical and clinical pregnancy rate, fertilization rate and&#xD;
      implantation rate will be compared between the two groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of follicles</measure>
    <time_frame>baseline</time_frame>
    <description>Evaluation thre number follicles before injection of Human Chorionic Gonadotrophin (hCG)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Size of follicle</measure>
    <time_frame>baseline</time_frame>
    <description>Evaluation the size of follicle before injection of Human Chorionic Gonadotrophin (hCG)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endometrial thickness</measure>
    <time_frame>1day</time_frame>
    <description>Evaluation the endometrial thickness at the day of injection of Human Chorionic Gonadotrophin (hCG)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of oocytes retrieved</measure>
    <time_frame>3 days</time_frame>
    <description>Evaluation the number of oocytes retrieved 34-36 hours after Human Chorionic Gonadotrophin (hCG) injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fertilization rate</measure>
    <time_frame>2 days</time_frame>
    <description>Evaluation the fertilization rate 2-3 days before the embryo transfer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical pregnancy rate</measure>
    <time_frame>2 weeks</time_frame>
    <description>Evaluation the biochemical pregnancy rate 2 weeks after embryo transfer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>4 weeks</time_frame>
    <description>Evaluation the clinical pregnancy rate 4-6 weeks after embryo transfer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>4 weeks</time_frame>
    <description>Evaluation the implantation rate 4-6 weeks after embryo transfer.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Luveris</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Evaluation the effect of Luveris protocol on Induction of ovulation in Patients with Hypogonadotropic Hypogonadism</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gonal-F&amp; Luveris</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Evaluation the effect of Gonal-F&amp; Luveris protocols of Induction of ovulation in Patients with Hypogonadotropic Hypogonadism</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lutropin alfa</intervention_name>
    <description>Administration of Gonal-F or recombinant Follicle Stimulating Hormone (rFSH)</description>
    <arm_group_label>Luveris</arm_group_label>
    <other_name>Follitropin alfa: Gonal-F or recombinant Follicle Stimulating Hormone (rFSH)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Follitropin alfa and Lutropin alfa</intervention_name>
    <description>Administration of (rFSH) and (rLH)</description>
    <arm_group_label>Gonal-F&amp; Luveris</arm_group_label>
    <other_name>Follitropin alfa: Gonal-F or recombinant Follicle Stimulating Hormone (rFSH) and</other_name>
    <other_name>Lutropin alfa: Luveris or Recombinant Luteinizing Hormone (rLH)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a clinical history of hypogonadotropic hypogonadism, and laboratory test result&#xD;
             comply with diagnosis of hypogonadotropic hypogonadism&#xD;
&#xD;
          -  Have discontinued gonadotropins or gonadotropin releasing hormone or&#xD;
             estrogen-progesterone replacement therapy at least one month before the study&#xD;
&#xD;
          -  Have primary or secondary amenorrhea&#xD;
&#xD;
          -  Serum Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) &lt;5.0 IU/l and&#xD;
             oestradiol &lt;100 pg/ml before initiation of treatment&#xD;
&#xD;
          -  Have a negative progesterone challenge test&#xD;
&#xD;
          -  Normal serum concentrations of thyroid stimulating hormone (TSH), prolactin and&#xD;
             testosterone within 6 months before the start of study&#xD;
&#xD;
          -  Be willing and able to comply with the protocol for the duration of the study&#xD;
&#xD;
          -  Have given written informed consent prior to any study related procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The other causes of infertility.&#xD;
&#xD;
          -  History of ovarian hyper stimulation syndrome&#xD;
&#xD;
          -  Abnormal gynecological bleeding of undetermined origin&#xD;
&#xD;
          -  Previous or current hormone dependent tumor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hamid Gourabi, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Head of Royan Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tahereh Madani, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Endocrinology and Female Infertility at Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seyedeh Masoumeh Moosavi Sadat, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Endocrinology and Female Infertility, Reproductive Biomedicine Research Centre, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nasser Aghdami, MD,PhD</last_name>
    <phone>(+98)2123562000</phone>
    <phone_ext>516</phone_ext>
    <email>nasser.aghdami@royaninstitute.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leila Arab, MD</last_name>
    <phone>(+98)2123562000</phone>
    <phone_ext>414</phone_ext>
    <email>Leara91@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royan Institute</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nasser Aghdami, MD,PhD</last_name>
      <phone>(+98)2123562000</phone>
      <phone_ext>516</phone_ext>
      <email>nasser.aghdami@royaninstitute.org</email>
    </contact>
    <contact_backup>
      <last_name>Leila Arab, m</last_name>
      <phone>(+98)23562000</phone>
      <phone_ext>414</phone_ext>
      <email>Leara91@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Reza Khalili, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jhaleh Etminan, Bsc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>sdamaneh Jalali, BSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <link>
    <url>http://Royaninstitute.org</url>
    <description>Related Info</description>
  </link>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>May 14, 2014</study_first_submitted>
  <study_first_submitted_qc>May 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2014</study_first_posted>
  <last_update_submitted>May 5, 2015</last_update_submitted>
  <last_update_submitted_qc>May 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gonal-F Luveris Assisted Reproductive Technology Hypogonadotropic Hypogonadism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

